Objective: To compare the ameliorating effects of carvedilol and nebivolol on kidney Ischemia/Reperfusion Injury (IRI).Materials and Methods: A total of 24 rats were separated into 4 groups. The experimental model group and 2 treatmentgroups underwent right nephrectomy and left ischemia/reperfusion. The sham group underwent laparotomy. Carvedilol ornebivolol was administered between the first and sixth days to the treatment groups. On the sixth day, an experimental IRImodel was created by right nephrectomy and left renal arterial clamping, followed by reperfusion. After reperfusion, kidneyfunction markers and kidney injury molecule levels were determined, histological examinations were carried out, a tissueoxidative product level, and the antioxidant enzyme activities were measured. Results: All groups showed similar basal results. The nebivolol and carvedilol groups did not show differences in the kidneyfunctions and the injury molecules vs. the experimental model group. Only the carvedilol group’s Kidney-Injury-Molecule-1(KIM-1) levels showed statistically significant amelioration. The carvedilol and nebivolol groups only showed significanteffect on the tissue with Glutathione S-Transferase activity. The carvedilol group showed attenuated tubular congestioncompared with the experimental model group. Other histological findings were similar between all groups. Conclusion: In our study, both carvedilol and nebivolol failed to show any benefits against IRI on a single-kidney experi mental model in terms of routine kidney function tests, Malondialdehyde levels, Superoxide Dismutase and Catalase activ ities, and histological findings. Both molecules had favorable effects on the tissue with Glutathione S-Transferase activity.Carvedilol showed a better ameliorating effect on urinary KIM-1 levels and histological tubular congestion scores.